Quarterly ResultMay 7, 2026, 04:12 PM
Corvus Pharmaceuticals Raises $189.4M in Offering; Q1 Net Loss $(13.7)M
AI Summary
Corvus Pharmaceuticals completed a follow-on public offering in January 2026, raising approximately $189.4 million in net proceeds. For the first quarter ended March 31, 2026, the company reported a net loss of $13.7 million, a significant change from the net income of $15.2 million in the prior year period. This offering substantially increased the company's cash, cash equivalents, and marketable securities to $236.7 million, providing liquidity to fund planned operations for at least the next 12 months. Research and development expenses also increased to $11.2 million as the company continues its clinical development programs.
Key Highlights
- Follow-on public offering generated $189.4M net proceeds in January 2026.
- Q1 2026 net loss was $(13.7)M, compared to $15.2M net income in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $236.7M as of March 31, 2026.
- Total assets increased to $253.2M from $71.1M at December 31, 2025.
- Stockholders' equity rose to $240.7M from $61.2M at December 31, 2025.
- Research and development expenses increased to $11.2M from $7.5M year-over-year.
- Basic net loss per share was $(0.15) for Q1 2026.
- Company believes current cash is sufficient to fund operations for at least the next 12 months.
Price Impact
More from CRVS